Not a good future

Quote

anonymous

Guest
"Biogen is rumored to be looking to acquire a smaller drugmaker to replenish both its lineup and pipeline. But that does nothing to improve the company’s immediate prospects, which look highly uncertain. The best-case scenario for Biogen would be for the CMS to relax coverage restrictions on Aduhelm and for the medicine to finally live up to the hype — or something close to it.

But even if the CMS gets behind Aduhelm, it is unlikely to be nearly as successful as it needs to be for Biogen to reverse course, and here’s why. Even though many AD patients and their families will no doubt welcome Aduhelm, given the negative publicity, it seems likely that other patients, their families, and even some physicians might still be firmly on the side of the skeptics. Further, several other companies are working on potential AD treatments, including Eli Lilly.

Biogen also does have another investigational AD therapy in the works, along with many other pipeline candidates. In the long run, the company could recover from its current struggles. But at the moment, Biogen does not look like a particularly attractive stock. There are much better biotech stocks to consider buying right now."

2 Red Flags for Biogen's Future | citybiz
 












What about Tysabri sc being denied and going generic next year ? Outch,
Biogen has not prepared for any of this loss just wasted millions on aduhell.
Great lifecycle management. How do you screw up a new formulation submission?
Why isn’t Aaa been canned yet. The woke woman live on
 




























































anonymous said:
Then leave
Click to expand...

Are you watching? Everyone IS leaving. And, many of the people who are still here are sitting on job offers with a start date after April 11, hoping that the CMS decision goes south so that they can get severance and a new job. You can count on the fact that at least 50% of those still here will leave shortly after April 11, regardless of the CMS decision.
 






anonymous said:
Are you watching? Everyone IS leaving. And, many of the people who are still here are sitting on job offers with a start date after April 11, hoping that the CMS decision goes south so that they can get severance and a new job. You can count on the fact that at least 50% of those still here will leave shortly after April 11, regardless of the CMS decision.
Click to expand...

my new partner will be gone by next week and I will be gone shortly thereafter. Good things RBMs got those great raises and bonuses. If the NCD changes for the better, they are going to have to become TBMs. I can’t even fathom what kind of bottom feeders they will get to fill the vacant spots in that scenario. Positive NCD or not, everyone knows that this has been a disaster. Many of the national infusion accounts have already stated that they aren’t willing to take new patients until the ASP kicks back in at the beginning of July.
 






























I cant imagine working in the biosimilar unit. There is no future there. Too my Lucentis biosimilar drugs will be out and it will always go to the lowest price. You can't sell on price.
 












Top Bottom
Back
Quote